Advertisement
Advertisement
U.S. markets open in 2 hours 51 minutes
S&P Futures
4,289.25 -9.00 (-0.21%) Dow Futures
33,805.00 -68.00 (-0.20%) Nasdaq Futures
13,651.25 -30.00 (-0.22%) Russell 2000 Futures
2,019.80 -4.00 (-0.20%) Crude Oil
88.79 -0.62 (-0.69%) Gold
1,789.10 -9.00 (-0.50%)
Aeglea BioTherapeutics, Inc. (AGLE)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-Market:
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 0.4920 |
| Open | 0.5000 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 1000 |
| Day's Range | 0.4710 - 0.5258 |
| 52 Week Range | 0.3720 - 8.5000 |
| Volume | |
| Avg. Volume | 681,027 |
| Market Cap | 31.736M |
| Beta (5Y Monthly) | 1.77 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0940 |
| Earnings Date | Nov 02, 2022 - Nov 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.58 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Subscribe to Yahoo Finance Plus to view Fair Value for AGLE
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Aeglea BioTherapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 03/21/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat5 months agoArgus Research
- Zacks
Aeglea Biotherapeutics (AGLE) Reports Q2 Loss, Lags Revenue Estimates
Aeglea (AGLE) delivered earnings and revenue surprises of -3.85% and 55.99%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Aeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program Updates
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the second quarter ended June 30, 2022 and provided program updates.
- Simply Wall St.
Here's Why Aeglea BioTherapeutics (NASDAQ:AGLE) Must Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
